Quick Answer
Mirum Pharmaceuticals, Inc. reported Operating Income Loss of -$22.14 million for the year ending 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +74.7% in Operating Income Loss from 2024 to 2025.
- This data is from Mirum Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$65.0 thousand | Q1 2019: -$6.18 million | Q2 2019: -$14.03 million | Q3 2019: -$15.87 million | Q1 2020: -$22.03 million | Q2 2020: -$23.60 million | Q3 2020: -$21.72 million | Q1 2021: -$47.61 million | Q2 2021: -$37.40 million | Q3 2021: -$42.82 million | Q1 2022: -$32.74 million | Q2 2022: -$31.44 million | Q3 2022: -$32.88 million | Q1 2023: -$27.15 million | Q2 2023: -$24.27 million | Q3 2023: -$25.15 million | Q1 2024: -$26.47 million | Q2 2024: -$24.23 million | Q3 2024: -$12.68 million | Q1 2025: -$15.18 million | Q2 2025: -$4.99 million | Q3 2025: $2.60 million.
- Over the full 7 years of available data (2019 to 2025), Mirum Pharmaceuticals, Inc.'s Operating Income Loss has grown by 59.6%.
- Historical annual values: Fiscal year 2025: -$22.14 million | Fiscal year 2024: -$87.61 million | Fiscal year 2023: -$109.15 million | Fiscal year 2022: -$131.22 million | Fiscal year 2021: -$173.41 million | Fiscal year 2020: -$104.30 million | Fiscal year 2019: -$54.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: